Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOptiBiotix Health Regulatory News (OPTI)

Share Price Information for OptiBiotix Health (OPTI)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 18.00
Bid: 17.50
Ask: 18.50
Change: 0.00 (0.00%)
Spread: 1.00 (5.714%)
Open: 18.00
High: 18.00
Low: 18.00
Prev. Close: 18.00
OPTI Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Launch of Slimbiome in Nutri-bites

8 Mar 2018 07:00

RNS Number : 9874G
OptiBiotix Health PLC
08 March 2018
 

OptiBiotix Health plc

("OptiBiotix" or the "Company")

 Launch of Slimbiome® in Nutri-bites®

 

OptiBiotix Health plc (AIM:OPTI), a life sciences business developing compounds to tackle obesity, and high cholesterol, announces the launch of its award winning SlimBiome® in Nutri-Bites® with its US partner, Cereal Ingredients ("CII"), at the 2018 Natural Products Expo West & Engredea. The exhibition is the world's largest trade show for organic, natural and healthy products and typically attract more than 80,000 food and ingredient buyers from around the world. OptiBiotix will join CII at stand 3788.

 

OptiBiotix has partnered with specialty ingredients manufacturer CII Ingredients, to launch its patented weight management technology, SlimBiome® in CII's Nutri-Bites® range of cereal based food products. This extends SlimBiome® applications from snack bars and shakes to breakfast cereals and bakery products (e.g. cookies, cakes and tortillas) as well as increasing the range of options for healthy snacks, yoghurts and cereal bars.

 

Products in the Nutri-Bites® range contain expanded cereal pieces and are formulated with a choice of protein sizes and content. These can be applied to granola and snack mix inclusions, nutritional and cereal bars and coated snacks, or just used as a healthy crunch topping.

 

This is a continuation of OptiBiotix's focus on the US market following last years supply & manufacturing Aareement with CII, announced on 12 December 2017. SlimBiome® is the first in a range of products which helps to improve human health through the science of the microbiome. Other products under development in the range include ImmunoBiome, ® CardioBiome® and WellBiome®.

 

Cereal Ingredients is a privately held speciality ingredients manufacturer based in Kansas, USA, dedicated to the development, manufacture and supply of unique, high-quality food ingredients which contribute a meaningful point of difference.

 

Christina Wood, OptiBiotix Sales and Marketing Director, said: "Many cereals and snack bars on the market are deceptively high in sugar and calories, leading consumers with healthy intentions who use these products to gain, rather than lose, weight. By combining OptiBiotix's award winning SlimBiome® technology with CII's market-leading ingredients manufacturing capacity and product development, we have created a delicious functional solution which can help customers manage their weight by reducing snacking and food intake without food cravings. We are delighted to share this innovative science based approach to weight management with food and ingredient buyers from around the world at the Natural Products Expo West & Engredea show."

 

For more information about Optibiotix, please visit www.optibiotix.com

 

 

 

For further information, please contact:

 

OptiBiotix Health plc

www.optibiotix.com

Stephen O'Hara, Chief Executive

Contact via Walbrook below

Walbrook PR Ltd

Tel: 020 7933 8780 or optibiotix@walbrookpr.com

Anna Dunphy

Mob: 07876 741 001

 

About OptiBiotix - www.optibiotix.com

OptiBiotix was formed in March 2012 to develop compounds which modify the human microbiome - the collective genome of the microbes in the body - to prevent and manage human disease.

 

The aim of OptiBiotix is to discover and develop microbial strains, compounds and formulations, which modulate the human microbiome and can be used as food ingredients and supplements or active compounds for the prevention and management of human metabolic diseases, examples of which include obesity, cholesterol and lipid distribution and diabetes.

 

OptiBiotix has established a pipeline of microbiome modulators that can impact on lipid and cholesterol management, energy harvest and appetite suppression. The development pipeline is fuelled by its proprietary OptiScreen® and OptiBiotic® platform technologies designed to identify metabolic pathways and compounds that impact on human physiology and bring potential health benefits.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NRAUBSARWSAORAR
Date   Source Headline
20th Jul 20227:00 amRNSCommercial and scientific update
11th Jul 20227:00 amRNSJoint development agreement signed with Firmenich
1st Jul 20227:00 amRNSDirector Appointment and Director Dealing
28th Jun 20227:00 amRNSFinal Results
20th Jun 20227:00 amRNSProBiotix Health - Appointment of CEO
31st Mar 20227:01 amRNSAdmission of ProBiotix Health plc to AQSE
25th Mar 20222:36 pmRNSDirector/PDMR Shareholding
18th Mar 20222:00 pmRNSPrice Monitoring Extension
17th Mar 20227:00 amRNSIntention to list ProBiotix Health on AQSE
9th Mar 20227:00 amRNSExercise of warrants
1st Mar 20227:00 amRNSCommercial Appointments
28th Feb 20227:00 amRNSTrading Update
9th Feb 20227:00 amRNSCommercial and strategy update
1st Feb 20227:00 amRNSConsumer study of LPLDL in Cholbiome products
27th Jan 202210:38 amRNSExercise of Warrants
18th Jan 20227:00 amRNSPublication of third human study on LPLDL
7th Jan 20227:00 amRNSIssue of options
5th Jan 20227:00 amRNSOptiBiotix obtains BRC accreditation
15th Dec 20217:00 amRNSExclusive sales and distribution agreement
9th Dec 20217:00 amRNSLaunch of GoFigure range with Apollo Hospitals
1st Dec 202112:00 pmRNSInvestor presentation
1st Dec 20217:00 amRNSLaunch of LeanBiome with global nutrition leader
17th Nov 20217:00 amRNSFormation of OptiBiotix Health India
15th Nov 20214:59 pmRNSHolding(s) in Company
25th Oct 20217:00 amRNSSlimBiome® Approved by Health Canada
30th Sep 20217:00 amRNSHalf-year Report
1st Sep 20217:00 amRNSDirector/PDMR Shareholding
31st Aug 20217:00 amRNSDirector dealing
31st Aug 20217:00 amRNSInvestor update
10th Aug 20217:00 amRNSExtension of territories for Seed Health’s DS-01
5th Aug 20217:00 amRNSTrading and commercial update
9th Jul 202110:49 amRNSResult of AGM
6th Jul 20217:00 amRNSFurther sales expansion in Asia
17th Jun 20217:00 amRNSFinal Results
19th May 20212:00 pmRNSSkinBioTherapeutics plc shareholding
21st Apr 20217:00 amRNSDirector/PDMR Shareholding
16th Apr 20217:00 amRNSDirector’s Dealing
23rd Mar 20217:00 amRNSDirectorate Changes
17th Mar 20217:00 amRNSCommercial strategy update
2nd Mar 20217:00 amRNSDirector Appointment
24th Feb 20217:00 amRNSInvestor update
18th Feb 20217:00 amRNSStrategy and commercial update
2nd Feb 20217:00 amRNSProposed Director appointment
19th Jan 20217:00 amRNSNew appointments
12th Jan 20217:00 amRNSChange of broker
11th Jan 20217:00 amRNSResearch study
7th Jan 20214:41 pmRNSSecond Price Monitoring Extn
7th Jan 20214:36 pmRNSPrice Monitoring Extension
5th Jan 20217:00 amRNSDirectorate Change
9th Dec 20207:00 amRNSProposed Director appointment and Director change

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.